For the Inventor, By the Inventor

Enter assignee name

Vancouver, Canada

Cardiome Pharma Corp.

Calculating rank

USPTO Granted Patents = 36

% Expired Patents = 13.9

CIPO Patents = 4

EPO Patents = 3

Trademarks = 3

Forward Citations = 297

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

Bertrand M C Plouvier (24 out of 27 patents)

Gregory N Beatch (20 out of 26 patents)

Doug Ta Hung Chou (14 out of 17 patents)

4. Tao Sheng (13 out of 13 patents)

5. Michael J A Walker (11 out of 16 patents)

6. Grace Jung (11 out of 11 patents)

7. Richard A Wall (11 out of 15 patents)

8. Jeff Jiqun Zhu (10 out of 20 patents)

9. Sandro L Yong (8 out of 8 patents)

10. Alexander B Zolotoy (8 out of 9 patents)

11. Alan M Ezrin (7 out of 14 patents)

12. Lewis Siu Leung Choi (7 out of 7 patents)

13. James Gee Ken Yee (6 out of 10 patents)

14. Anthony G M Barrett (5 out of 10 patents)

15. Cindy J Longley (5 out of 7 patents)

Core Competencies:

Aminocyclohexyl Ether Compounds

Ion Channel Modulating Compounds

Dosing Regimens

Synthetic Processes

Prodrugs

Drug Conjugates

Deuterated Compounds

Cycloalkyl Amine Compounds

Imidazo[1,2-α]Pyridine Ether Compounds

Aminocycloalkyl Cinnamide Compounds

Compositions for Modulating Activity

Indole-Containing Compounds

36 patents: Sort by Forward Citations

1. 9586899 - Synthetic process for aminocyclohexyl ether compounds (2017-03-07),

2. 9115081 - Synthetic process for aminocyclohexyl ether compounds (2015-08-25),

3. 8692002 - Synthetic process for aminocyclohexyl ether compounds (2014-04-08),

4. 8618311 - Synthetic processes for the preparation of aminocyclohexyl ether compounds (2013-12-31),

5. 8344162 - Synthetic processes for the preparation of aminocyclohexyl ether compounds (2013-01-01),

6. 8263638 - Dosing regimens for ion channel modulating compounds (2012-09-11),

7. 8207219 - Ion channel modulating activity I (2012-06-26),

8. 8188140 - Uses of ion channel modulating compounds (2012-05-29),

9. 8163938 - Aminocyclohexyl ether compounds and uses thereof (2012-04-24),

10. 8080673 - Synthetic processes for the preparation of aminocyclohexyl ether compounds (2011-12-20),

11. 8058304 - Merged ion channel modulating compounds and uses thereof (2011-11-15),

12. 8022098 - Deuterated aminocyclohexyl ether compounds and processes for preparing same (2011-09-20),

13. 8008342 - Ion channel modulating compounds and uses thereof (2011-08-30),

14. 7977373 - Prodrugs of ion channel modulating compounds and uses thereof (2011-07-12),

15. 7875611 - Ion channel modulating compounds and uses thereof (2011-01-25),

Company Overview

Cardiome Pharma Corp. is a biopharmaceutical company based in Vancouver, Canada, specializing in the development of innovative therapies for cardiovascular diseases. The organization focuses on addressing unmet medical needs through its research and development efforts, particularly in the areas of heart rhythm disorders and heart failure. Cardiome is committed to advancing treatment options that improve patient outcomes and enhance quality of life, leveraging its expertise in drug development and clinical research.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

36 Patents

#18 in Vancouver

#376 in Canada

#18,762 in the World

Vancouver, Canada

Cardiome Pharma Corp.

Forward Citations = 297

50 inventors:

Bertrand M C Plouvier (24 out of 27 patents)

Gregory N Beatch (20 out of 26 patents)

Doug Ta Hung Chou (14 out of 17 patents)

4. Tao Sheng (13 out of 13 patents)

5. Michael J A Walker (11 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cardiome Pharma Corp.. Retrieved from https://idiyas.com/company/cardiome-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…